GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cytek Biosciences Inc (NAS:CTKB) » Definitions » Price-to-Operating-Cash-Flow

Cytek Biosciences (Cytek Biosciences) Price-to-Operating-Cash-Flow : 154.00 (As of Apr. 29, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Cytek Biosciences Price-to-Operating-Cash-Flow?

As of today (2024-04-29), Cytek Biosciences's share price is $6.16. Cytek Biosciences's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.04. Hence, Cytek Biosciences's Price-to-Operating-Cash-Flow Ratio for today is 154.00.

The historical rank and industry rank for Cytek Biosciences's Price-to-Operating-Cash-Flow or its related term are showing as below:

CTKB' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 45.64   Med: 189.07   Max: 1111
Current: 154.02

During the past 5 years, Cytek Biosciences's highest Price-to-Operating-Cash-Flow Ratio was 1111.00. The lowest was 45.64. And the median was 189.07.

CTKB's Price-to-Operating-Cash-Flow is ranked worse than
96.14% of 440 companies
in the Medical Devices & Instruments industry
Industry Median: 21.465 vs CTKB: 154.02

Cytek Biosciences's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $0.07. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.04.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -54.90% per year.

During the past 5 years, Cytek Biosciences's highest 3-Year average Operating Cash Flow per Share Growth Rate was 12.20% per year. The lowest was -54.90% per year. And the median was -21.35% per year.


Cytek Biosciences Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Cytek Biosciences's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytek Biosciences Price-to-Operating-Cash-Flow Chart

Cytek Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Operating-Cash-Flow
- - 286.32 - 233.85

Cytek Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 552.00 233.85

Competitive Comparison of Cytek Biosciences's Price-to-Operating-Cash-Flow

For the Medical Devices subindustry, Cytek Biosciences's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cytek Biosciences's Price-to-Operating-Cash-Flow Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cytek Biosciences's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Cytek Biosciences's Price-to-Operating-Cash-Flow falls into.



Cytek Biosciences Price-to-Operating-Cash-Flow Calculation

Cytek Biosciences's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=6.16/0.04
=154.00

Cytek Biosciences's Share Price of today is $6.16.
Cytek Biosciences's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

Cytek Biosciences Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Cytek Biosciences's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Cytek Biosciences (Cytek Biosciences) Business Description

Traded in Other Exchanges
Address
47215 Lakeview Boulevard, Fremont, CA, USA, 94538
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance.
Executives
Patrick Jeanmonod officer: Chief Financial Officer C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Ming Yan director, officer: Chief Technology Officer C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Wenbin Jiang director, officer: President and CEO C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Philippe Busque officer: SVP, Global Sales and Services 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
Jack Ball director C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Paul Christopher Williams officer: Chief Operating Officer C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
Don M Hardison director
Deborah J Neff director C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BLVD., FREMONT CA 94538
Jonathan Todd Garland officer: Chief Commercial Officer C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
Ra Capital Healthcare Fund Lp director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Vera Imper director C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
Theresa Cameron director C/O THERAPEUTICS ACQUISITION CORP., 200 BERKELEY STREET. 18TH F L, BOSTON MA 02116
Feng Deng director SUITE 1701, 17/F HUTCHISON HOUSE, 10 HARCOURT ROAD, CENTRAL, HONG KONG K3 00000
Ra Capital Nexus Fund Ii, L.p. director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116